Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Lymphoid 3Head & Neck 3Thoracic 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 12Colorectal Neoplasms 8Lung Neoplasms 7Ovarian Neoplasms 6Neoplasms 5Mesothelioma, Malignant 5Carcinoma, Renal Cell 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Merkel Cell 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

pembrolizumab 39Nivolumab 13Cisplatin 12Paclitaxel 11Docetaxel 11Carboplatin 10atezolizumab 9Trastuzumab 9Gemcitabine 9Cyclophosphamide 8fludarabine 7Bevacizumab 7aldesleukin 6durvalumab 5Taxes 5Oxaliplatin 5Magnetic Resonance Spectroscopy 5Leucovorin 5Irinotecan 5Fluorouracil 5130-nm albumin-bound paclitaxel 5avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Ipilimumab 4Drug Therapy 4Cetuximab 4Capecitabine 4Albumin-Bound Paclitaxel 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Interleukin-2 × Thoracic × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡